Perfil de la empresa · Healthcare

Certara Inc

CERT · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
11 de diciembre de 2020
Empleados
1515
Precio actual
$5.54
En vivo · 18 de junio de 2026
Compra razonable
≤ $4.1
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
47/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $5.54 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador $3.6–$4.1 / razonable $5.2–$7 / optimista $9.5–$11. A $5.54, Dentro del rango de valor intrínseco razonable.

Al publicar $5.27 (12 de junio de 2026)

Aún no hay análisis sobre este valor en tu idioma.

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Capitalización810,49 MUS$
Ingresos (TTM)419,75 MUS$
EBITDA94,03 MUS$
Margen neto-3,6 %
ROE-1,44 %
PER previsto12,67
BPA-0,10 US$
Rango de 52 semanas4,45 US$ – 13,88 US$
Precio objetivo de analistas7,48 US$
Recomendación de analistas3.8 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.